Ischemia-modified albumin (IMA) is increased in patients with chronic hepatitis C infection and related to markers of oxidative stress and inflammation.

Zuwała−Jagiełło, Jolanta; Warwas, Maria; Pazgan−Simon, Monika

doi:10.18388/abp.2012_2107

Cited by 25 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, they found that IMA levels were higher in patients with hemorrhage when compared to patients without hemorrhage. A similar relationship was revealed by Zuwała-Jagiełło et al between IMA and inflammation in chronic hepatitis C patients with diabetes [48].…”

Section: Study (Number Of Patients) [Reference Number] Usefulsupporting

confidence: 85%

Role of ischemia-modified albumin in clinical practice

Erenler

Yardan

Katı

et al. 2015

LaboratoriumsMedizin

View full text Add to dashboard Cite

Difficulty in establishing a diagnosis of acute coronary syndrome (ACS) in the clinical setting has led researchers to investigate novel markers that show increased blood levels before the myocardial necrosis occurs. In ischemic conditions, some modifications occur in the amino acids located on the N-terminus of the human albumin molecule. Ischemia-modified albumin (IMA) is a marker formed after damage in the N-terminal region of albumin. The altered N-terminus can no longer bind transition metals, such as cobalt. The causes of the increases in IMA have been shown to be endothelial or extracellular hypoxia, acidosis, and free oxygen radicals. IMA, an early marker of ischemic disorders, is also a candidate marker for the detection of ACS. An assay measuring IMA might represent a promising marker for the identification of patients with myocardial ischemia. The aim of this study was to evaluate the clinical utility of IMA in the assessment of ACS as well as other medical disorders in light of the recent literature.

show abstract

Section: Study (Number Of Patients) [Reference Number] Usefulsupporting

confidence: 85%

Role of ischemia-modified albumin in clinical practice

Erenler

Yardan

Katı

et al. 2015

LaboratoriumsMedizin

View full text Add to dashboard Cite

show abstract

“…One of the objectives of the current study was to investigate the association between IM and bilirubin. It has been demonstrated that oxidative stress serves a crucial role in the pathogenesis of various infections, including the hepatitis virus ( 37 ), respiratory viruses ( 38 ), human immunodeficiency virus ( 39 ), influenza virus ( 40 ), Staphylococcus aureus ( 41 ), Helicobacter pylori ( 42 ) and mycoplasma ( 43 ). It is hypothesized that an infection due to EBV may also cause oxidative stress, leading to the marked depletion of antioxidants, such as bilirubin.…”

Section: Discussionmentioning

confidence: 99%

Infectious mononucleosis and hepatic function

et al. 2018

View full text Add to dashboard Cite

Abnormal hepatic function is common in infectious mononucleosis (IM). However, it remains unknown why increased transferase levels are more common than bilirubin abnormalities in IM. The current study aimed to investigate these associations in the Chinese population. A total of 95 patients with IM (47 males and 48 females) were enrolled in the current study, as well as 95 healthy controls. Patients were sorted by sex. A receiver operating characteristic (ROC) curve was used to determine cut-off values for IM diagnosis and prediction. Crude and adjusted odds ratios (OR) for IM were analyzed using binary logistic regression. It was determined that alanine aminotransferase (ALT), aspartate aminotransferase (AST) and γ-glutamyl transferase (GGT) levels were significantly higher in patients with IM compared with controls; however, total bilirubin (TB) levels were significantly lower in patients with IM. ROCs demonstrated that, if ALT, AST and GGT concentrations were higher than, or if TB was lower than, cut-off values, they were predictive of IM. Binary logistic regression identified that the risk of IM in patients exhibiting high levels of transferases was significantly increased, particularly in males. Crude ORs in ALT quartile 4 were 21.667 and 10.111 for males and females, respectively and adjusted ORs were 38.054 and 9.882, respectively. A significant IM risk of IM was evident in patients with low bilirubin levels and females appeared to be particularly susceptible. For example, crude ORs in quartile 1 were 8.229 and 8.257 for males and females, respectively and adjusted ORs were 8.883 and 10.048, respectively. Therefore, the current study identified a positive association between transferase levels and IM and a negative association between TB and IM. Therefore, the results of the current study indicate that high transferases are suggestive of IM, particularly in males, whereas low TB is suggestive for IM, particularly in females.

show abstract

“…These authors found that oxidative stress occurred in CHC patients and serum levels of AOPPs were significantly elevated compared to the control group. Zuwała‐Jagiełło et al studied AOPPs in 63 patients with CHC infection. The plasma levels of AOPPs in the patients with CHC infection were significantly higher than those in healthy subjects.…”

Section: Data Sourcesmentioning

confidence: 99%

Advanced oxidation protein products play critical roles in liver diseases

Zhao

Zhang

Ouyang

et al. 2019

Eur J Clin Investigation

View full text Add to dashboard Cite

There is a complex oxidant and antioxidant system that maintains the redox homoeostasis in the liver. While suffering from exogenous or endogenous risk factors, the balance between oxidants and antioxidants is disturbed and excessive reactive oxygen species are generated, resulting in oxidative stress. Oxidative stress is prevalent in various liver diseases and is thought to be involved in their pathophysiology. Advanced oxidation protein products are generated under conditions of oxidative damage and are newly described protein markers of oxidative stress. Previous studies have underscored the universal pathogenic roles of oxidation protein products in various diseases. However, investigations into how these products participate in the development of liver diseases have been superficial and insufficient. In this review, we highlight the current understanding of the roles of advanced oxidation protein products in liver disease pathogenesis and the underlying mechanisms. Moreover, we summarize the current studies on advanced oxidation protein products in infectious and noninfectious, acute and chronic liver diseases. Different strategies for targeting these advanced oxidation protein products and future perspectives, which may pave the way for developing new therapeutic strategies, will also be discussed here.

show abstract

Ischemia-modified albumin (IMA) is increased in patients with chronic hepatitis C infection and related to markers of oxidative stress and inflammation.

Cited by 25 publications

References 31 publications

Role of ischemia-modified albumin in clinical practice

Role of ischemia-modified albumin in clinical practice

Infectious mononucleosis and hepatic function

Advanced oxidation protein products play critical roles in liver diseases

Contact Info

Product

Resources

About